At the end of today’s hearings, an FDA advisory panel will issue recommendations about whether manufacturers of electroconvulsive devices must put their devices to rigorous safety tests or whether they should be reclassified from Class III (high risk) to Class II (moderate risk)> Below are critical comments by Professor John Read (University of Auckland, New…

Read More

The latest psychotherapy fad is "cybertherapy embraces escapism and the mechanized techniques of "virtual reality." It has been given a veneer of legitimacy by a prominent article in the New York Times "Science" section. 

Read More

Pharma Efforts to Bar Placebo Responders from Trials – WSJ Fri, 25 Jun 2004 A clinical trial report in The Lancet debunks the value of Aricept, a popular drug prescribed for Alzheimer’s patients. The findings of a three-year placebo controlled trial show that: “Although the patients taking the drug did have slightly higher scores on…

Read More

Commonly recommended Treatments found Worthless Wed, 19 Mar 2003 Independent analyses of the clinical studies upon which widely recommended drug treatments have been based, have now been found to be fatally faulty, and the drugs are deemed worthless. An analysis of 83 studies found that drugs used to treat 90,000 hospitalized babies and toddlers with…

Read More

Reply to the American College of Neuropharmacology’s Report on SSRI and Suicidal Behavior in Children Jonathan Leo, Ph.D. Introduction The American College of Neuropsychopharmacology (ACNP) recently released an Executive Summary from its Task Force on SSRIs and Suicidal Behavior. The task force concluded that "taking Selective Serotonin Reuptake Inhibitors (SSRIs) or other new generation antidepressant…

Read More

Next Phase in Psychiatry? Or, NIMH Effort to Rescue Bad Drugs – WSJ Fri, 29 Jul 2005 The Wall Street Journal uncritically reported: “The results of the largest studies ever conducted of depression and schizophrenia will be released in coming months, potentially transforming the way patients are treated and shaking up some of the drug…

Read More

Are SSRIs and Atypical Antidepressants Safe / Effective for Children / Adolescents/ Neonates? Wed, 2 Mar 2005 The American psychiatric establishment continues to operate within a “head in the sand” culture of denial when confronted with compelling evidence that has been scientifically replicated showing that their prescribing of antidepressants for children has been misguided. They…

Read More

ADHD drug – Cylert withdrawn from market due to Liver Toxicity, a Major Risk of Psychotropic Drugs Tue, October 25, 2005 The FDA announced that another drug prescribed for ADHD–Cylert–was removed from the US market for safety reasons. On September 25, 2005, the Associated Press reported: “Eli Lilly said it provided the FDA results from…

Read More

Pharma’s Pervasive Influence Corrupts Medicine both sides of Atlantic Tue, 4 Oct 2005 The focus of criticism in medicine has shifted from cost and barriers to access to treatments to an examination of the safety and benefit of current treatments. The pharmaceutical industry’s corrupting influence on physicians, academic researchers, the lay and professional journals, and…

Read More